US Pharma MarketingGSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides.
Source: FierceBiotech